Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286297761> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W4286297761 endingPage "TPS8592" @default.
- W4286297761 startingPage "TPS8592" @default.
- W4286297761 abstract "TPS8592 Background: A standard of care treatment for most patients with stage II and III non-small cell lung cancer (NSCLC) and a PD-L1 > 1% is surgery followed by adjuvant (adj) histology-specific chemotherapy followed by 1 year of atezolizumab. The benefit of adding atezolizumab concomitantly to chemotherapy in the adj setting has not been reported. In addition, the optimal duration of adjuvant therapy is undefined. Emerging data have demonstrated the potential for ctDNA to predict clinical recurrence in patients with surgically resected lung, breast, and colon cancer. The current study explores the predictive value of ctDNA for early relapse in patients treated with adj chemotherapy plus atezolizumab. Methods: The LUN19-396 is a phase II biomarker study that enrolls pts with resected NSCLC stage IB (tumors ≥ 4cm), IIA, IIB, and select IIIA (T3N1-2, T4N0-2). The ctDNA will be assessed within 60 days post-surgery and then every 3 months up to 12 months. All pts will receive treatment with 4 cycles of Cisplatin 60-75mg/m2 + Docetaxel 60-75mg/m2 + Atezolizumab 1200mg IV on day 1 q 3w (for patients with squamous cell cancer) or Cisplatin 60-75mg/m2 + Pemetrexed 500mg/m2 + Atezolizumab 1200mg on day 1 IV q 3w (for patients with non-squamous cell), followed by up to 13 additional cycles of Atezolizumab 1200mg IV every 3w. This trial will enroll a total of 100 pts to achieve more than 80% power. The primary objective is to estimate the percentage of pts with detectable ctDNA after surgery who have clearance of ctDNA at designated time points during adjuvant therapy. The key secondary objective is to estimate the 1-year disease-free survival in pts with undetectable ctDNA after 4 cycles of adj chemotherapy plus atezolizumab who had detectable ctDNA after surgery. This trial has enrolled 17 pts as of February 8, 2022. Clinical trial information: NCT04367311." @default.
- W4286297761 created "2022-07-21" @default.
- W4286297761 creator A5002970130 @default.
- W4286297761 creator A5038756644 @default.
- W4286297761 creator A5048331793 @default.
- W4286297761 creator A5058710250 @default.
- W4286297761 creator A5065305886 @default.
- W4286297761 creator A5074428655 @default.
- W4286297761 creator A5076708638 @default.
- W4286297761 date "2022-06-01" @default.
- W4286297761 modified "2023-09-26" @default.
- W4286297761 title "Assessing the predictive value of ctDNA on relapse in patients with resected stage IB-IIIA NSCLC treated with adjuvant chemotherapy plus concomitant atezolizumab followed by atezolizumab: BTCRC LUN 19-396." @default.
- W4286297761 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.tps8592" @default.
- W4286297761 hasPublicationYear "2022" @default.
- W4286297761 type Work @default.
- W4286297761 citedByCount "2" @default.
- W4286297761 countsByYear W42862977612023 @default.
- W4286297761 crossrefType "journal-article" @default.
- W4286297761 hasAuthorship W4286297761A5002970130 @default.
- W4286297761 hasAuthorship W4286297761A5038756644 @default.
- W4286297761 hasAuthorship W4286297761A5048331793 @default.
- W4286297761 hasAuthorship W4286297761A5058710250 @default.
- W4286297761 hasAuthorship W4286297761A5065305886 @default.
- W4286297761 hasAuthorship W4286297761A5074428655 @default.
- W4286297761 hasAuthorship W4286297761A5076708638 @default.
- W4286297761 hasConcept C121608353 @default.
- W4286297761 hasConcept C126322002 @default.
- W4286297761 hasConcept C141071460 @default.
- W4286297761 hasConcept C143998085 @default.
- W4286297761 hasConcept C146357865 @default.
- W4286297761 hasConcept C151730666 @default.
- W4286297761 hasConcept C2775949291 @default.
- W4286297761 hasConcept C2776256026 @default.
- W4286297761 hasConcept C2776694085 @default.
- W4286297761 hasConcept C2777240266 @default.
- W4286297761 hasConcept C2777701055 @default.
- W4286297761 hasConcept C2777863537 @default.
- W4286297761 hasConcept C2778239845 @default.
- W4286297761 hasConcept C2779384505 @default.
- W4286297761 hasConcept C2780057760 @default.
- W4286297761 hasConcept C2781190966 @default.
- W4286297761 hasConcept C71924100 @default.
- W4286297761 hasConcept C86803240 @default.
- W4286297761 hasConceptScore W4286297761C121608353 @default.
- W4286297761 hasConceptScore W4286297761C126322002 @default.
- W4286297761 hasConceptScore W4286297761C141071460 @default.
- W4286297761 hasConceptScore W4286297761C143998085 @default.
- W4286297761 hasConceptScore W4286297761C146357865 @default.
- W4286297761 hasConceptScore W4286297761C151730666 @default.
- W4286297761 hasConceptScore W4286297761C2775949291 @default.
- W4286297761 hasConceptScore W4286297761C2776256026 @default.
- W4286297761 hasConceptScore W4286297761C2776694085 @default.
- W4286297761 hasConceptScore W4286297761C2777240266 @default.
- W4286297761 hasConceptScore W4286297761C2777701055 @default.
- W4286297761 hasConceptScore W4286297761C2777863537 @default.
- W4286297761 hasConceptScore W4286297761C2778239845 @default.
- W4286297761 hasConceptScore W4286297761C2779384505 @default.
- W4286297761 hasConceptScore W4286297761C2780057760 @default.
- W4286297761 hasConceptScore W4286297761C2781190966 @default.
- W4286297761 hasConceptScore W4286297761C71924100 @default.
- W4286297761 hasConceptScore W4286297761C86803240 @default.
- W4286297761 hasFunder F4320332193 @default.
- W4286297761 hasIssue "16_suppl" @default.
- W4286297761 hasLocation W42862977611 @default.
- W4286297761 hasOpenAccess W4286297761 @default.
- W4286297761 hasPrimaryLocation W42862977611 @default.
- W4286297761 hasRelatedWork W2007167792 @default.
- W4286297761 hasRelatedWork W2088420067 @default.
- W4286297761 hasRelatedWork W2167650070 @default.
- W4286297761 hasRelatedWork W2235272930 @default.
- W4286297761 hasRelatedWork W2358450743 @default.
- W4286297761 hasRelatedWork W2363975552 @default.
- W4286297761 hasRelatedWork W2511367473 @default.
- W4286297761 hasRelatedWork W2765444947 @default.
- W4286297761 hasRelatedWork W3032772405 @default.
- W4286297761 hasRelatedWork W3180757786 @default.
- W4286297761 hasVolume "40" @default.
- W4286297761 isParatext "false" @default.
- W4286297761 isRetracted "false" @default.
- W4286297761 workType "article" @default.